CLOs on the Move


 
Getting together with real people in real life makes powerful things happen. Side hustles become careers, ideas become movements, and chance encounters become lifelong connections. Meetup brings people together to create thriving communities. Show up. Change lives. To continue to help these tight-knit communities grow -- and to help new ones form -- we are rapidly growing our teams to maximize our impact on lives. We are ready to reshape and rebuild Meetup for the mobile, global future, and to craft experiences that echo the amazing feeling of going to a great meetup in real life. Our team is bold, supportive, and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.meetup.com
  • 632 Broadway
    New York, NY USA 10012
  • Phone: 212.255.7327

Executives

Name Title Contact Details
David Diesenhouse
General Counsel Profile

Similar Companies

RDI Technologies

Vibration Monitoring Equipment that uses Motion Amplification® to find issues with manufacturing equipment. Start preventing downtime with motion analysis.

Lumivero

Lumivero is a software company that provides data analysis and management tools to collect, organize, and analyze data to create insights that drive positive collaborations and impactful decisions.

Browz LLC

Browz LLC is one of the leading providers in Software and Internet. It is based in Draper, UT. To find more information about Browz LLC, please visit www.browz.com.

ThoroughCare

ThoroughCare is a healthcare software company focused on patient assessments and chronic care management solutions for providers and health systems.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.